Economic Evaluation of Ipilimumab in First Line Treatment of Advanced Melanoma in Italy:

Global & Regional Health Technology Assessment

MariaDe Francesco¹ 

关键词: Advanced melanoma;    First line treatment;    Ipilimumab;    Micro-costing;   

DOI  :  10.5301/GRHTA.5000230

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

BackgroundIpilimumab, a fully human monoclonal antibody that blocks CTLA-4 to promote anti-tumour immunity, was the first treatment in metastatic melanoma to show a significant survival benefit.MethodsA three-health-state partitioned survival model was developed to assess ipilimumab 3 mg/kg compared to dacarbazine and vemurafenib in first line therapy of advanced melanoma treatment-naive patients in Italy. The outcomes considered were costs, life years (LYs) and quality-adjusted life years (QALYs). Given the lack of trials assessing ipilimumab 3 mg/kg in this subgroup of patients, the efficacy was derived from a dataset of chemo-naive patients. Patient's management costs were estimated based on a micro-costing approach and the cost of adverse events based on both outpatient and inpatient care. Utilities considered were elicited from ipilimumab's clinical trials.ResultsBasecase results showed that ipilimumab was both more costly and more effective than dacarbazine, with ratios of €38,345/LYs and €49,466/QA...

【 授权许可】

CC BY